The SPARTACUS Trial: Controversies and Unresolved Issues

Area of Science:

• Endocrinology
• Nephrology
• Surgical Innovation

Background:

• Adrenal vein sampling (AVS) is the gold standard for differentiating unilateral from bilateral primary aldosteronism (PA).
• Accurate diagnosis guides treatment: surgery for unilateral disease (aldosterone-producing adenomas) and medical therapy for bilateral disease (adrenal hyperplasia).
• AVS is invasive, lacks standardization, and is available only in specialized centers, prompting research into simpler diagnostic methods.

Purpose of the Study:

• To evaluate if adrenal vein sampling (AVS) is superior to adrenal imaging for primary aldosteronism (PA) differential diagnosis.
• To compare clinical outcomes in patients treated based on AVS results versus those treated based on imaging alone.

Main Methods:

• The SPARTACUS trial, a multicenter study, randomized patients with PA.
• One group received treatment guided by AVS results; the other group received treatment guided solely by abdominal imaging results.
• Clinical outcomes were assessed one year after treatment initiation.

Main Results:

• No significant difference in clinical outcomes was observed between the AVS-guided and imaging-guided treatment groups after one year.
• The study challenged the necessity of AVS as the sole determinant for treatment decisions in PA.

Conclusions:

• The SPARTACUS trial suggests that abdominal imaging may be sufficient for guiding treatment decisions in primary aldosteronism, potentially simplifying the diagnostic algorithm.
• The findings have sparked debate regarding the role and necessity of AVS in routine clinical practice for PA management.